Case-Only Designs in Pharmacoepidemiology: A Systematic Review

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Nordmann, Sandra ^a   Biard, Lucie ^b   Ravaud, Philippe ^c   Esposito Farèse, Marina ^b   Tubach, Florence ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ARTICLE; DRUG SAFETY; HUMAN; MEDICAL DOCUMENTATION; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW; VACCINATION; VALIDATION PROCESS;

CROSS-OVER STUDIES; EPIDEMIOLOGIC RESEARCH DESIGN; MEDLINE; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY; RESEARCH DESIGN;

EID: 84869217884     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049444     Document Type: Article

References (31)

1. Maclure M, (1991) The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 133: 144-53.
2. Suissa S, (1995) The case-time-control design. Epidemiology 6: 248-53.
3. Farrington CP, (1995) Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 51: 228-35.
4. Farrington CP, (1993) Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 22: 742-6.
5. Petri H, de Vet HC, Naus J, Urquhart J, (1988) Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescription drugs in large populations. Stat Med 7: 1171-5.
6. Viboud C, Boelle PY, Kelly J, Auquier A, Schlingmann J, et al. (2001) Comparison of the statistical efficiency of case-crossover and case-control designs: application to severe cutaneous adverse reactions. J Clin Epidemiol 54: 1218-27.
7. Schneeweiss S, Sturmer T, Maclure M, (1997) Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 6Suppl 3: S51-9.
8. Janes H, Sheppard L, Lumley T, (2005) Overlap bias in the case-crossover design, with application to air pollution exposures. Stat Med 24: 285-300.
9. Whitaker HJ, Farrington CP, Spiessens B, Musonda P, (2006) Tutorial in biostatistics: the self-controlled case series method. Stat Med 25: 1768-97.
10. Greenland S, (1996) Confounding and Exposure Trends in Case-Crossover and Case-Time-Control Designs Epidemiology. 7(3): 231-9.
11. Piegorsch WW, Weinberg CR, Taylor JA, (1994) Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med 13: 153-62.
12. Albert PS, Ratnasinghe D, Tangrea J, Wacholder S, (2001) Limitations of the Case-only Design for Identifying Gene-Environment Interactions. Am. J. Epidemiol. 154 (8): 687-693.
13. The Self-controlled case series website. http://statistics.open.ac.uk/sccs/. (Accessed 2012, July 18th).
14. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, et al. (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. Epidemiology 18: 805-35.
15. Vines SK, Farrington CP, (2001) Within-subject exposure dependency in case-crossover studies. Stat Med 20: 3039-49.
16. Farrington CP, (2004) Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 22: 2064-70.
17. Farrington CP, Nash J, Miller E, (1996) Case series analysis of adverse reactions to vaccines: A comparative evaluation. Am J Epidemiol 143 (11): 1165-73.
18. Musonda P, Farrington CP, Whitaker HJ, (2006) Sample sizes for self-controlled case series studies. Stat Med 25: 2618-2631.
19. Farrington CP, Whitaker HJ, (2006) Semiparametric analysis of case series data. J Royal Stat Soc, Series C 55: 553-94 (with discussion).
20. Martín-Rodríguez J, Albavera-Hernández C, Salazar-Martínez E, (2010) Case-crossover studies: a conceptual and methodological approach. Gac Med Mex 146(1): 37-43.
21. Carracedo-Martínez E, Tobías A, Saez M, Taracido M, Figueiras A, (2009) Case-crossover design: Basic essentials and applications. Gac Sanit 23(2): 161-5.
22. Maclure M, (2007) 'Why me' versus 'why now' - difference between operational hypotheses in case-control versus case-crossover studies. Pharmacoepidemiol Drug Saf 16: 850-853.
23. Farrington CP, Whitaker HJ, Hocine MN, (2009) Case series analysis for censored, perturbed, or curtailed post-event exposures. Biostatistics 10: 3-16.
24. Farrington CP, Anaya K, Whitaker HJ, Hocine MN, Douglas I, et al. (2011) Self-Controlled Case Series Analysis with Event-Dependent Observation Periods. J Am Stat Assoc 106(494): 417-26.
25. Weldeselassie YG, Whitaker HJ, Farrington CP, (2011) Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiol Infect. 139(12): 1805-17.
26. Xu S, Zhang L, Nelson JC, Zeng C, Mullooly J, et al. (2011) Identifying optimal risk windows for self-controlled case series studies of vaccine safety. Stat Med 30(7): 742-52.
27. Maclure M, Mittleman MA, (2000) Should we use a case-crossover design? Annu. Rev. Public Health 21: 193-221.
28. Smeeth L, Donnan PT, Cook DG, (2006) The use of primary care databases: case-control and case-only designs. Fam Pract 23: 597-604.
29. Kuhnert R, Hecker H, Poethko-Müller C, Schlaud M, Vennemann M, et al. (2011) A modified self-controlled case series method to examine association between multidose vaccinations and death. Stat Med 30(6): 666-77.
30. Grosso A, Douglas I, Macallister R, Petersen I, Smeeth L, et al. (2011) Use of the self-controlled case series method in drug safety assessment. Expert Opin Drug Saf. 10(3): 337-40.
31. Maclure M, Fireman B, Nelson JC, Hua W, Shoaibi A, et al. (2012) When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf. 21(S1): 50-61.